Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1968 3
1984 2
1985 3
1986 2
1987 5
1988 7
1989 11
1990 10
1991 14
1992 10
1993 12
1994 16
1995 24
1996 10
1997 16
1998 16
1999 7
2000 23
2001 14
2002 9
2003 26
2004 26
2005 25
2006 27
2007 21
2008 43
2009 32
2010 31
2011 38
2012 24
2013 35
2014 44
2015 48
2016 46
2017 74
2018 56
2019 69
2020 81
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

906 results
Results by year
Filters applied: . Clear all
Page 1
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, Bataille V, Marmol VD, Dummer R, Harwood CA, Hauschild A, Höller C, Haedersdal M, Malvehy J, Middleton MR, Morton CA, Nagore E, Stratigos AJ, Szeimies RM, Tagliaferri L, Trakatelli M, Zalaudek I, Eggermont A, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Peris K, et al. Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003. Epub 2019 Jul 6. Eur J Cancer. 2019. PMID: 31288208 Review.
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. ...Radiotherapy represents a valid alternative to surgery for BCC on the face, especially in elderly patients. In patients with naevoid basal cell carcinoma
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. ...Radiotherapy represents a valid
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Gershenwald JE, et al. CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13. CA Cancer J Clin. 2017. PMID: 29028110 Free PMC article.
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed sinc …
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a lar …
Epidemiology of skin cancer.
Leiter U, Eigentler T, Garbe C. Leiter U, et al. Adv Exp Med Biol. 2014;810:120-40. doi: 10.1007/978-1-4939-0437-2_7. Adv Exp Med Biol. 2014. PMID: 25207363 Review.
Melanoma and nonmelanoma skin cancer (NMSC) are now the most common types of cancer in white populations. ...An intensive UV exposure in childhood and adolescence was causative for the development of basal cell carcinoma (BCC) wher
Melanoma and nonmelanoma skin cancer (NMSC) are now the most common types of cancer in white populations. ...An
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Robert C, et al. N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4. N Engl J Med. 2019. PMID: 31166680 Clinical Trial.
BACKGROUND: Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. ...CONCLUSIONS: First-line treatment with …
BACKGROUND: Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free …
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Dummer R, et al. Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21. Lancet Oncol. 2018. PMID: 29573941 Clinical Trial.
BACKGROUND: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF(V600)-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafe …
BACKGROUND: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF(V600)-mutant advanced melanoma. We investigated enco …
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Van Allen EM, et al. Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10. Science. 2015. PMID: 26359337 Free PMC article.
Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response t …
Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable c …
Epidemiology of Skin Cancer: Update 2019.
Leiter U, Keim U, Garbe C. Leiter U, et al. Adv Exp Med Biol. 2020;1268:123-139. doi: 10.1007/978-3-030-46227-7_6. Adv Exp Med Biol. 2020. PMID: 32918216 Review.
Melanoma and keratinocyte skin cancer (KSC) are the most common types of cancer in White-skinned populations. Both tumor entities showed increasing incidence rates worldwide but stable or decreasing mortality rates. Rising incidence rates of cutaneous
Melanoma and keratinocyte skin cancer (KSC) are the most common types of cancer in White-skinned populations. Bo
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Hofmann L, et al. Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13. Eur J Cancer. 2016. PMID: 27085692
BACKGROUND: Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. ...METHODS AND FINDINGS: In total, 496 patients with metastatic melanoma from 15 …
BACKGROUND: Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanom
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Menzer C, et al. J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3. J Clin Oncol. 2019. PMID: 31580757
PURPOSE: BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K-mutated metastatic melanoma. For patients with less frequent BRAF mutations, however, efficacy data are limited. ...Multivariable analyses revealed superior survival (PFS and overall survival …
PURPOSE: BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K-mutated metastatic melanoma. For patients with less …
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Long GV, et al. Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176. Ann Oncol. 2017. PMID: 28475671 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. Patients were randomized to receive dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or dab …
PATIENTS AND METHODS: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage II …
906 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page